|
Colorectal Carcinoma
|
0.510 |
Biomarker
|
disease |
BEFREE |
Here we identify DACT3, a member of the DACT (Dpr/Frodo) gene family, as a negative regulator of Wnt/beta-catenin signaling that is transcriptionally repressed in colorectal cancer.
|
18538736 |
2008 |
|
Townes syndrome
|
0.510 |
GeneticVariation
|
disease |
BEFREE |
Together, these findings suggest that the DACT1 c.1256G>A nonsense variant is causative of a specific genetic syndrome with features overlapping Townes-Brocks syndrome.
|
28054444 |
2017 |
|
Anus, Imperforate
|
0.110 |
Biomarker
|
disease |
BEFREE |
A heterozygous nonsense variant was identified in dapper, antagonist of beta-catenin, 1 (DACT1) via whole-exome sequencing in family members with imperforate anus, structural renal abnormalities, genitourinary anomalies, and/or ear anomalies.
|
28054444 |
2017 |
|
Congenital ear anomaly NOS (disorder)
|
0.110 |
Biomarker
|
group |
BEFREE |
A heterozygous nonsense variant was identified in dapper, antagonist of beta-catenin, 1 (DACT1) via whole-exome sequencing in family members with imperforate anus, structural renal abnormalities, genitourinary anomalies, and/or ear anomalies.
|
28054444 |
2017 |
|
Neoplasms
|
0.070 |
PosttranslationalModification
|
group |
BEFREE |
Promoter CpG methylation of DACT1 was detected in five (55.6%) of nine breast cancer cell lines and 40 (29.9%) of 134 primary tumors, but not in surgical-margin tissues and normal breast tissues.
|
23497530 |
2013 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
DACT1 has been shown to participate in the development of many types of tumors; however, its role and precise molecular mechanisms in leukemia are unclear.
|
29037126 |
2017 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
The tumor suppressive effect of DACT1 was further confirmed by loss of DACT1 function experiment.
|
23073659 |
2012 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
We have shown that DACT1 promotes cancer cell proliferation in vitro and tumor growth in vivo and enhances the migratory and invasive potential of colon cancer cells.
|
22470507 |
2012 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
The clinical significance of aberrant promoter methylation of the canonical Wnt pathway antagonist genes (sFRP1, sFRP2, sFRP4, sFRP5, Wif1, Dkk3, and Hdpr1) and also putative tumor-suppressor gene Wnt5a, belonging to the non-canonical Wnt signaling pathway, was investigated in a large series of 75 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia by methylation-specific polymerase chain reaction.
|
18549404 |
2008 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
MiR-324-3p promotes tumor growth through targeting DACT1 and activation of Wnt/β-catenin pathway in hepatocellular carcinoma.
|
29029464 |
2017 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Only DKK4 exhibited similarly high methylation levels in both tumour and normal specimens, while DACT1 was always essentially unmethylated.
|
22672427 |
2012 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Mice with T2DM had lower pancreatic β-cell function and insulin sensitivity, as well as diminished expression of miR-125b-5p but enhanced expressions of DACT1, JNK and c-Jun. miR-125b-5p inhibited DACT1 expression and the activation of the JNK signaling pathway, as well as restrained cell proliferation and promoted cell apoptosis.
|
30684546 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
Biomarker
|
disease |
BEFREE |
The data showed that BM-MSCs from Mutant demonstrated a state of disease memory, depicted by an upregulated expression of inflammatory markers (IL-6, TNFα); increased stem cell recruitment (Oct-4, Sox-2) and proliferation rates (CD90+/CD29+, PDA, 'S' phase of cell cycle by FACS and BrdU incorporation); accelerated preadipocyte induction (Dact-1, PPARγ2) with a quantitative increase in mature adipocyte formation (Leptin); ILCAs, which were non-responsive to high glucose did confer the Obese/T2D memory in Mutants.
|
23144726 |
2012 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
Biomarker
|
disease |
BEFREE |
DAPPER (UMIN000025102) is a multicenter, randomized, open-labeled, parallel-group, standard treatment-controlled study, which is designed to evaluate whether dapagliflozin, one of the SGLT-2 inhibitors, decreases albuminuria in T2D patients with CHF and exerts cardioprotective effects on the failing heart.
|
29589153 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
Biomarker
|
disease |
BEFREE |
In conclusion, Dapper1 attenuates hepatic gluconeogenesis and lipogenesis in T2D.
|
28237722 |
2017 |
|
Neoplasm Metastasis
|
0.040 |
PosttranslationalModification
|
phenotype |
BEFREE |
DACT1 methylation was significantly associated with tumor metastasis (P < 0.05), invasion (P < 0.05) and advanced tumor stage (P < 0.0005).
|
23073659 |
2012 |
|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
High expression of DACT1 may inhibit the invasion and metastasis of nasopharyngeal carcinoma cells.
|
31182157 |
2019 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Dapper homolog 1 alpha suppresses metastasis ability of gastric cancer through inhibiting planar cell polarity pathway.
|
27833078 |
2016 |
|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Functional assays showed that ectopic expression of DACT1 could inhibit breast tumor cell proliferation in vivo and in vitro through inducing apoptosis, and further suppress tumor cell migration through antagonizing the Wnt/β-catenin signaling pathway.
|
23497530 |
2013 |
|
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
Cyclin G2 suppresses Wnt/β-catenin signaling and inhibits gastric cancer cell growth and migration through Dapper1.
|
30547803 |
2018 |
|
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
Dapper homolog 1 alpha suppresses metastasis ability of gastric cancer through inhibiting planar cell polarity pathway.
|
27833078 |
2016 |
|
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
Dapper homolog 1 is a novel tumor suppressor in gastric cancer through inhibiting the nuclear factor-κB signaling pathway.
|
23073659 |
2012 |
|
Carcinogenesis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Ectopic expression of DACT1 in silenced gastric cancer cell lines (AGS, BGC823 and MGC803) by stable transfection suppressed colony formation (P < 0.001), induced cell apoptosis (P < 0.01) and retarded tumorigenesis in nude mice (P < 0.001).
|
23073659 |
2012 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
It has been reported that DACT1 functions in embryonic development and tumorigenesis.
|
29136762 |
2018 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
DACT1 (Dapper/Frodo) has been identified as involved in antagonizing Wnt/β-catenin signaling through interacting with Dishevelled (Dvl), a central mediator of Wnt signaling, whereas its role in breast tumorigenesis remains unclear.
|
23497530 |
2013 |